Side-by-side · Research reference

LL-37vsN-Acetyl Epitalon Amidate

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AHuman-MechanisticHUMAN-REVIEWED15/35 cited

BAnimal-StrongHUMAN-REVIEWED12/45 cited

LL-37

Cathelicidin · Human AMP

Broad-spectrumAntimicrobial activity

Membrane disruptionPrimary mechanismLu 2026 He 2026

Innate immunityHost defense rolePinheiro 2026 Zhang 2026

Endogenous · Secreted at inflammation sites

N-Acetyl Epitalon Amidate

Bioregulator Tetrapeptide · Khavinson School

10 passagesExtra divisionsKhavinson 2004

Telomerase+Enzyme inductionKhavinson 2003

4-AATetrapeptide

SQ · Variable protocols

01Mechanism of Action

Parameter

LL-37

N-Acetyl Epitalon Amidate

Primary target

Bacterial membranes · Phosphatidylserine-exposed cellsHe 2026 Lu 2026

DNA promoter regions (telomerase, RNA polymerase II, retinal genes)

Pathway

hCAP-18 precursor → Proteinase-3 cleavage → LL-37 release → Membrane insertion/disruption

Peptide → DNA complementary binding → Gene transcription initiation → Telomerase catalytic subunit expression

Downstream effect

Membrane permeabilization, cytokine induction, autophagy, phagosome-lysosome fusion, chemotaxisAhmad 2026 Zhang 2026

Telomerase enzymatic activity induction, telomere elongation to early-passage length, extension of replicative lifespan in human somatic cellsKhavinson 2003 Khavinson 2004

Feedback intact?

—

Origin

Endogenous human cathelicidin (37-AA fragment, residues 134–170 of hCAP-18)

Synthetic tetrapeptide (Ala-Glu-Asp-Gly) derived from pineal extract bioregulator research; N-acetyl and C-amide modifications enhance plasma stability

Antibody development

—

02Dosage Protocols

Parameter

LL-37

N-Acetyl Epitalon Amidate

Endogenous expression

Constitutive in neutrophils, epithelial tissues

Upregulated during infection and inflammation.Pinheiro 2026

—

Exogenous (experimental)

Dose varies by study; antimalarial ~10–50 μM in vitro

No FDA-approved exogenous formulation.

—

Plasma levels (malaria)

Elevated in infected patients and miceHe 2026

Exogenous administration reduced parasitemia in murine models.He 2026

—

Evidence basis

In vitro, animal models, human observational

In vitro human cell cultureKhavinson 2004 Khavinson 2003

Standard dose

—

No standardized human dosing in indexed literature

In vitro protocols use direct culture addition; human clinical dosing protocols are in Russian-language literature outside PubMed scope.

Frequency

—

Not specified in candidate papers

Cell culture protocol

—

Addition to human fetal fibroblast culture induced telomerase activity and telomere elongation to early-passage lengthKhavinson 2004

Cells made 10 extra divisions (44 passages total vs 34 in control).

Duration

—

Chronic treatment in aging culture

Sustained effect through late passages.

Modification stability

—

N-acetyl + C-amide caps enhance peptidase resistance

Standard strategy for tetrapeptide stabilization; specifics not quantified in candidates.

04Side Effects & Safety

Parameter

LL-37

N-Acetyl Epitalon Amidate

Cytotoxicity (high dose)

Membrane disruption in host cells at supraphysiological concentrations

—

Pro-inflammatory signaling

Can exacerbate inflammation in certain contexts (context-dependent)Pinheiro 2026

—

Biofilm formation risk

LL-37-DNA complexes may stabilize dental plaque biofilmsTanabe 2026

—

Theoretical cancer risk

Immunomodulatory roles in tumor microenvironment under investigation

—

Human safety data

—

Not available in indexed literature

Candidate papers describe in vitro and animal models only.

Theoretical telomerase risk

—

Telomerase activation in somatic cells raises theoretical oncogenic transformation concern

In vitro observations

—

No cytotoxicity reported in human fetal fibroblast cultureKhavinson 2004

Absolute Contraindications

LL-37

—

N-Acetyl Epitalon Amidate

·Active malignancy or history of cancer — telomerase reactivation may promote tumor cell immortalization

Relative Contraindications

LL-37

·Active autoimmune disease (theoretical immune dysregulation)

N-Acetyl Epitalon Amidate

·Individuals with hereditary cancer syndromes or high genetic cancer risk

05Administration Protocol

Parameter

LL-37

N-Acetyl Epitalon Amidate

1. Natural secretion

LL-37 is constitutively expressed in neutrophils and epithelial cells, cleaved from hCAP-18 by proteinase-3 at sites of infection or inflammation.

Subcutaneous injection assumed based on peptide class; no specific protocol in candidate papers.

2. Experimental formulations

Synthetic LL-37 and derivatives (e.g., SAMP-12aa) tested in vitro and animal models. Administered via topical, intraperitoneal, or intravenous routes in research settings.

Standard bacteriostatic water for lyophilized peptides. Exact volume not specified in indexed literature.

3. Stability considerations

LL-37 is resistant to pepsin degradation at gastric pH. Synthetic short peptides designed to retain this stability while reducing toxicity.Lu 2026

Lyophilized: -20 °C, desiccated. Reconstituted: refrigerate 2–8 °C. N-acetyl and C-amide modifications improve stability vs unprotected tetrapeptide.

4. Clinical protocols

—

Human dosing schedules published in Russian-language clinical literature; not indexed in PubMed candidate set.

06Stack Synergy

LL-37

— no documented stacks

N-Acetyl Epitalon Amidate

+ Thymalin

Moderate

View Thymalin →

Both are Khavinson-school bioregulators with epigenetic mechanisms. Thymalin targets thymic transcription factors for immune function, while Epitalon targets telomerase and pineal-axis genes. Combined use theoretically addresses dual axes of aging: replicative senescence and immune decline. Multi-target bioregulator strategy per Khavinson gerontology framework.

Epitalon: Protocol not defined in indexed literature
Thymalin: Tissue-specific bioregulator · separate dosing
Rationale: Complementary transcriptional targets
Primary benefit: Dual-axis aging intervention: cellular senescence + immune restoration